Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GelVac HPV vaccine is an investigational vaccine developed by DelSite Biotechnologies for the prevention of Human Papillomavirus (HPV) infection. It utilizes the proprietary GelVac delivery platform, which is based on the GelSite polymer—a high molecular weight ionic polysaccharide. This technology allows the vaccine to be formulated as a nasal powder or a reconstituted injection. A significant advantage of this platform is its ability to stabilize vaccines at room temperature, potentially eliminating the need for cold chain storage. The formulation is designed to be preservative-free and adjuvant-free, relying on the polymer's properties for delivery and potentially enhanced mucosal immunity when administered intranasally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GelVac HPV vaccine.